Current strategies for treatment of relapsed/refractory multiple myeloma
Authors:
- 29 January 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 7 (1) , 97-111
Abstract
(2014). Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology: Vol. 7, No. 1, pp. 97-111.Keywords
This publication has 109 references indexed in Scilit:
- Salvage Second Hematopoietic Cell Transplantation in MyelomaTransplantation and Cellular Therapy, 2013
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia, 2013
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administrationCancer Chemotherapy and Pharmacology, 2012
- Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyCancer Chemotherapy and Pharmacology, 2011
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)Leukemia, 2010
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionCancer, 2010
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999